Citation Impact
Citing Papers
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
The DNA-damage response in human biology and disease
2009 StandoutNature
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
EGFR Antagonists in Cancer Treatment
2008 Standout
Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells
2006
Pancreatic cancer
2004 Standout
Inflammation and cancer
2002 StandoutNature
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Matrix metalloproteases in head and neck cancer
2006
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
The molecular biology of head and neck cancer
2010 Standout
Cancer nanotechnology: opportunities and challenges
2005 Standout
Pancreatic Adenocarcinoma
2014 Standout
In vivo cancer targeting and imaging with semiconductor quantum dots
2004 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Gene therapy in pancreatic cancer
2014
Angiogenesis in life, disease and medicine
2005 StandoutNature
Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors
2005
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Matrix metalloproteinases as modulators of inflammation and innate immunity
2004 Standout
Thermo- and pH-responsive polymers in drug delivery☆
2006 Standout
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
2007 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Collagens—structure, function, and biosynthesis
2003 Standout
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
2011
Small cell lung cancer: the importance of the extracellular matrix
2004
Role of gemcitabine in cancer therapy
2005
Pancreatic Cancer
2010 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
2011
Designing dendrimers for biological applications
2005 Standout
Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer
2005
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
2006
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
The dawning era of polymer therapeutics
2003 Standout
Pancreatic cancer
2011 Standout
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis
2004
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
2006
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
2008
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
2013 StandoutNobel
Genes and pathways downstream of telomerase in melanoma metastasis
2006 StandoutNobel
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
2008
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
2023 StandoutNobel
The Pancreas Cancer Microenvironment
2012
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
2005
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
2003
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Works of J Schulz being referenced
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
2002
275 Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 4-fluorouracil-containing regimen
2003